JO
ASTX

John Overdeck’s ASTEX PHARMACEUTICALS, INC COM ASTX Stock Holding History

John Overdeck’s Portfolio ASTX Stock Details ASTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-201,292
Closed -$828K – 2356
2013
Q2 		$828K Buy
+201,292
New +$1.08M 0.01% 1197

Other funds holding ASTX

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WIC
Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return
SAM
Sandell Asset Management New York $179M AUM 65.55% 1-Year Est. Return

John Overdeck's ASTX Position: Q3 2013 in Review

John Overdeck sold out of ASTEX PHARMACEUTICALS, INC COM (ASTX) in Q3 2013, closing a stake of 201,292 shares — an estimated $828K sold.

John Overdeck first reported a position in ASTX in Q2 2013 and held it in 1 quarter. The position peaked at $828K in Q2 2013. 123 funds tracked by Wall St. Rank hold ASTX as of Q3 2013.

  • John Overdeck reported no remaining ASTEX PHARMACEUTICALS, INC COM position as of Q3 2013 after selling out during the quarter.
  • John Overdeck sold 201,292 ASTEX PHARMACEUTICALS, INC COM shares in Q3 2013, an estimated $828K.
  • John Overdeck first reported a position in ASTEX PHARMACEUTICALS, INC COM in Q2 2013 and held it in 1 quarter.
  • John Overdeck's ASTEX PHARMACEUTICALS, INC COM position peaked at $828K in Q2 2013.
  • 123 funds tracked by Wall St. Rank held ASTEX PHARMACEUTICALS, INC COM as of Q3 2013.

Based on Two Sigma Investments's 13F filing for Q3 2013, filed 14 Nov 2013.